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Abstract 
High-dose API powders which are to be tableted by direct compression should have high 
compactibility and compressibility. This note reports on a novel approach to the manufacture of 
crystalline powders intended for direct compaction with improved compactibility and 
compressibility properties. The poorly compactable API, chlorothiazide, was spray dried from a 
water/acetone solvent mix producing additive-free nanocrystalline microparticles (NCMPs) of 
median particle size 3.5 µm. Tablets compacted from NCMPs had tensile strengths ranging from 
0.5 to 4.6 MPa (compared to 0.6-0.9 MPa for tablets of micronised CTZ) at compression forces 
ranging from 6 kN to 13 kN. NCMP tablets also had high porosities (34-20%) and large specific 
surface areas (4.4 to 4.8 m2/g). The time taken for tablets made of NCMPs to erode was not 
statistically longer (p>0.05) than for tablets made of micronised CTZ. Fragmentation of NCMPs on 
compression was observed. The volume fraction of particles below 1 µm present in the suspension 
recovered after erosion of NCMP tablets was 34.8±3.43%, while no nanosized particles were 
detected in the slurry after erosion of compacted micronised CTZ. 
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The issues of tabletability of an API are important when the tablet is composed 
predominantly of the API (Augsburger and Hoag, 2008). Spray drying (SD) has been shown to 
improve tabletability of direct compression fillers such as lactose (SDL). Although SDL is an 
effective binder only at high loads over >80%, it is consequently not suitable in formulations of 
containing high-dose, poorly compactible APIs (Augsburger and Hoag, 2008).  
In the field of pharmaceutical nanotechnology, SD has been used to isolation of 
nanoparticles (Vergote et al., 2001) or to produce amorphous nanoparticles (Chow and Sun, 2004). 
Dolenc et al. (2009) reported on tableting of SD celecoxib nanoparticles, however assessed tablets 
comprised blends with microcrystalline cellulose. Limitations associated with production of 
nanoparticles include particle size control during precipitation/crystallisation, separation/drying of 
nanoparticles, conversion in a dry form and finally redispersion from powder to nanosuspension. 
Preparation of microparticles comprising nanocrystals can thus be regarded as a convenient 
approach to alleviate some of these limitations. Healy et al. (2008) reported that SD from a mixture 
of solvents can result in the formation of amorphous nanoporous microparticles, but no reports on 
nanocrystalline microparticles (NCMPs) manufactured using the mixed solvent approach have been 
published to date. 
This work presents SD/crystallisation of NCMPs composed of chlorothiazide (CTZ), a high-
dose API, previously shown to be crystalline when SD (Corrigan et al., 1984). The tabletability and 
erosion characteristics of NCMPs is assessed and compared to conventionally processed powders. 
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 SD of CTZ (Sigma, Germany) samples using conditions as outlined in table 1 was 
performed using a Büchi B-290 Mini Spray Dryer (Büchi 93001 en). Tablets (n=10) were 
compressed using a MTCM 1 tablet press (GlobePharma, USA), supplied with concave 10 mm 
diameter tooling. Tablets (n=10) were subjected to hardness test using Dr. Schleuniger-6D tablet 
tester (Pharmatron, UK). Erosion studies were performed in a vertically held glass vial (7.5x2 cm), 
equipped on the bottom with a 2 mm wire mesh and a tubing pumping in and out erosion medium 
(15 ml of 0.1M HCl at 37 ˚C) at the flow rate of 30 ml/min. Erosion time was defined as the time 
when all tablet fragments have passed through the wire mesh. Obtained suspensions were 
introduced to wet laser diffraction particle size analysis performed in 0.1 M HCl using a Hydro µP 
attachment with no ultrasound, using the pump speed of 1000 rpm and initial obscuration of 
20±2%. Solubility studies of CTZ in solvents were carried out in a shaking water bath at 50 rpm, for 
24 hours in 25 ˚C. Excess of CTZ was loaded into 10 ml glass vials, suspended in 5 ml of the 
solvent and vials hermetically sealed. The suspensions were filtered through a 0.2 µm membrane 
filter. Quantities of dissolved CTZ were assessed using UV spectrophotometry as described before 
(Paluch et al., 2010). Differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), 
powder XRD (PXRD) analysis, Fourier transform infrared spectroscopy (FTIR), scanning electron 
microscopy (SEM), specific surface area analysis (TBET) and particle size analysis by laser 
diffraction (dry method) were performed as described before (Paluch et al., 2011 and Tajber et al., 
2009).  
  
 The solubilities of CTZ in pure water (W) and acetone (AC) were 0.02% and 0.88% w/v, 
respectively. A maximum solubility of CTZ of 5.4% (w/v) in AC/W mixes was determined at 0.9 
AC volume fraction (Fig. A1.). The 9:1 AC/W v/v solvent mix was therefore selected for SD as the 
higher the SD feed concentration the greater may be the yield of the recovered powder. The 
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concentration of CTZ in the liquid was set initially to 5% w/v (CTZ5). The recovered particles were 
spherical and smooth (Fig. 1). The TBET of the sample was measured to be ~2.3 m2/g (Table 1).  
As CTZ5 did not render nanocrystallites, the feed concentration was decreased 10-fold 
(CTZ0.5). The CTZ0.5 particles were spherical with rough, porous surfaces (Fig. 1). CTZ0.5 
presented an increased TBET, ~10-fold comparing with CTZ starting material powder (CTZRaw) and 
2-fold in comparison to CTZ5 (Table 1). Particle size analysis showed that feed concentration had a 
significant (p<0.05) effect on the median particle size (d(50)) of SD CTZ. The d(50)s were 4.7 
(CTZ5) and 2.6 µm (CTZ0.5) (Table 1).  
SD from 0.5% CTZ w/v solution resulted however in a low production yield of about 51% 
and it was deemed unsatisfactory for tablet production. Therefore another batch of CTZ was 
produced using a feed concentration of 2% w/v (CTZ2). The change in feed concentration resulted 
in the production of microparticles composed of prismoidal nanocrystallites (Fig.1), with only a 
slight reduction of process yield to ~89% in comparison to CTZ5. SD of CTZ2 was carried out in 
the open blowing mode (in nitrogen atmosphere), mimicking the setup of industrial spray dryers. 
The TBET of CTZ2 was measured to be ~4 m2/g with the d(50) of 3.5 µm.  
 All CTZ SD samples were PXRD crystalline. The peak patterns were consistent with 
CTZRaw (Fig. A2). The DSC traces of CTZ5, CTZ0.5 and CTZ2 were superimposable with 
CTZRaw, with melting points ranging from ~370 °C to ~360 °C (~363.5 ˚C for CTZRaw, Fig. A3). 
TGA analysis indicated the residual solvent content for all SD systems was in the range from 0.1 to 
0.2%.  FTIR presented no visible band changes occurring in CTZ pre- and past-processing and all 
spectra of the samples were superimposable (Fig. A4).  
 
CTZRaw, CTZ5, CTZ2 as well as DipacTM, a commonly used direct compression 
binder/filler, were subjected to tableting. Compaction of CTZ5 in the range from 3 to 13 kN 
compression force (F) resulted in the production of either very brittle and fragile or 
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capped/laminated tablets thus only CTZ2 was investigated further. Tablets made of DipacTM at F as 
low as 3 kN presented a force to tensile failure (P) of 23.7±6.6 N (Fig. 2). The P values increased 
linearly with F at the rate of 23.6 N/kN (Table A1). In comparison, for CTZRaw the P values 
initially increased with increasing F and then fell off at F over 10 kN. The P values comparable to 
DipacTM compressed at 3 kN was recorded for CTZRaw only at F at and above 6 kN (Fig. 2). CTZ2 
presented improved compactibility of the API. The tablet formed at 3 kN had a P value of 
26.5±23.85 N, which was slightly higher than for DipacTM, but the rate of change of P versus F of 
8.1 N/kN was nearly 3 times lower than for DipacTM. 
Among DipacTM, CTZRaw and CTZ2 the largest porosity, of 33.74%, was recorded for the 
CTZ2 system at F of 3 kN (Fig.3). Tablets formed from CTZRaw at 6 kN had lower porosity of 
20.5% and significantly (p<0.05) lower tensile strength (σt) of 0.6 MPa in comparison to those 
formed from CTZ2 (Fig. 2). Also the porosity of CTZRaw was higher than for DipacTM at 6 kN F 
and DipacTM presented a greater σt of 1.08 MPa. The porosity of CTZ2 tablets decreased by about 
13.5% while σt increased by 4.1 MPa.  
Analysis of changes of TBET of DipacTM (Fig. 4) indicated that the original TBET of 0.2 m2/g 
measured for powder started to increase when compacted at 3 and 6 kN. The TBET reached a plateau 
at 10 kN. In contrast to DipacTM, CTZRaw did not show a tendency of TBET to decrease over the 
range of tested compression forces from 6 to 13 kN. The TBET measured for the powder (0.51 m2/g) 
was seen to increase in tablets. This indicated that CTZRaw compacted into tablets predominantly 
due to crushing and interlocking. CTZ2 behaved differently. The TBET of loose powder was 3.92 
m2/g and increased slightly for the material compressed under 3 kN to 4.75 m2/g and under 6 kN to 
4.8 m2/g, only to drop to 4.44 m2/g when F of 10 kN was applied.  
Tablets with comparable tensile strength, CTZRaw compressed at 6 kN and CTZ2 
compressed at 3 kN, were subjected to erosion studies. Tablets made of CTZRaw eroded in 13±4 
min, while CTZ2 tablets eroded in 17±3 min. No significant differences (p<0.05) in the 10th 
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percentile diameter (d(0.1)), d(0.5) and fractions of particles below 0.2 µm (<0.2 µm) and 1 µm (<1 
µm) were observed for uncompressed particles of CTZRaw and suspension of eroded CTZRaw 
tablets (Table 2). This suggests that compaction of CTZRaw does not affect the micromeritic 
properties of the particles.  
In contrast, d(0.1), d(0.5) and fractions  <0.2 µm and <1 µm were all statistically different 
for uncompressed CTZ2 and suspension of eroded CTZ2 tablets (Table 2). The d(0.1) and d(0.5) 
values were lower for the sample collected from erosion studies compared with the equivalent 
values for the uncompressed CTZ2, while the <0.2 µm and <1 µm fractions were significantly 
(p<0.05) greater (5.7±0.3% versus 27.3±4.6% and 18.1±1.9% versus 34.8±3.4%, respectively) for 
the eroded  tablet and uncompressed CTZ2, respectively. This is consistent with the observation 
depicted in Fig. 4 showing that TBET increased upon compaction of CTZ2 at 3kN suggesting that 
fragmentation of NCMPs occurs when tableted. 
 In conclusion, NCMPs of CTZ presented improved tabletability, as observed from 
the force to tensile failure, tensile strength and tablet porosity versus compression force 
relationships, in comparison to micronised and SD nonporous CTZ. The NCMPs also maintained 
large TBET on compression. Up to approximately 35% (by volume) of nanoparticulate material were 
observed to be released from the compacted NCMPs. The approach presented here whereby 
nanoparticles may be crystallised, dried and agglomerated to form microparticles in a one-step 
continuous process by SD presents a simplification over other production processes for 
nanocrystals/nanoparticles. 
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Tables  
Table 1. List of the analysed samples, with SD conditions, production yields, specific surface areas 
(TBET) and median particle size (d(50)) for the various  CTZ samples and Dipac™. 
Sample Solvent 
system 
Feed 
conc.  
[% w/v] 
Inlet 
temp 
[°C] 
Outlet 
temp 
[°C] 
Yield 
[%] 
Mode* TBET 
[m2/g] 
d(50) 
[µm] 
CTZraw N/A N/A N/A N/A N/A N/A 0.50±0.00 12.6±0.1 
CTZ5 AC/W 9:1 v/v 5.0 80 54 ~95 CM 2.26±0.06 4.7±0.1 
CTZ0.5 AC/W 9:1 v/v 0.5 80 53 ~51 CM 4.55±0.07 2.6±0.1 
CTZ2 AC/W 9:1 v/v 2.0 120 99 ~89 OM 3.9±0.13 3.5±0.1 
DipacTM N/A N/A N/A N/A N/A N/A 0.21±0.03 178.4±0.6 
 
* AC-acetone, W-water, OM–open mode, CM-closed mode. Regardless on the drying mode the 
feed rate was set to 10 ml/min and drying gas flow rate of 473 norm litres per hour was used.  
 
Table 2. Particle size distribution characteristics (d(0.1) and d(0.5)) and fraction of particles below 
0.2 and 1 µm in 0.1M HCl for sample CTZRaw and CTZ2 before compression (P CTZRaw) and (P 
CTZ2) and suspensions recovered after erosion (T CTZRaw) and (T CTZ2) (n=3).  
 
Sample d(0.1) [µm] d(0.5) [µm] <0.2 µm [%] <1 µm [%] 
P CTZRaw 12.201±0.367 30.206±0.292 0.00±0.00 3.3±0.23 
T CTZRaw 11.026±0.718 28.847±1.129 0.00±0.00 3.8±0.15 
P CTZ2 0.216±0.029 17.181±2.448 5.7±0.34 18.1±1.85 
T CTZ2 0.150±0.017 8.564±1.578 27.3±4.56 34.8±3.43 
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 Figures 
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CTZ2                                                                        CTZ2-T 
 
Fig. 1. SEM images of: CTZRaw powder, CTZRaw-T (the cross section of the tablet compressed of 
CTZRaw at 6 kN), CTZ5 powder, CTZ0.5 powder, CTZ2 powder and CTZ2-T (the cross section of 
the tablet compressed of CTZ2 at 6kN).  
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Fig. 2. Tensile strength (σt) versus compression force (F) for DipacTM, CTZRaw and CTZ2. Error 
bars express relative standard deviation (σr) for comparison purposes. 
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Fig. 3. Porosity of the tablet (εt) in relation to compression force (F) for DipacTM, CTZRaw and 
CTZ2. 
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Fig. 4. Specific surface area of the tablet (TBET) in relation to compression force (F) for: DipacTM, 
chlorothiazide raw material (CTZRaw) and CTZ nanocrystalline microparticles (CTZ2). 
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Appendix A 
 
Table A1. Compilation of tablet parameters: force to tensile failure (P), tensile strength (σt), tablet 
porosity (εt) and TBET against compression force (F). σr- relative standard deviation. 
Formulation F [kN] P [N](σr) σt [MPa](σr) εt [%](σr) TBET [m2/g] 
CTZRaw 
6 24.10(19.80) 0.60(0.49) 20.50(0.31) 0.78±0.02 
10 34.20(12.99) 0.92(0.35) 15.75(0.12) 0.81±0.02 
13 32.56(19.43) 0.90(0.54) 13.50(0.09) 0.88±0.01 
 
CTZ2 
3 26.50(23.85) 0.53(0.31) 33.74(0.41) 4.75±0.05 
6 108.30(30.71) 2.38(0.39) 26.45(0.37) 4.80±0.06 
10 190.40(37.58) 4.63(0.31) 20.26(0.33) 4.44±0.04 
 
DipacTM 
3 23.70(6.62) 0.47(0.13) 23.80(0.11) 0.50±0.03 
6 49.50(10.27) 1.08(0.22) 17.53(0.21) 0.77±0.02 
10 80.00(3.95) 1.80(0.09) 15.42(0.17) 0.87±0.03 
13 105.80(4.34) 2.55(0.10) 11.14(0.43) 0.83±0.01 
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Fig. A1. Solubility of CTZ in acetone, water and acetone/water mixtures.  
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Fig. A2. PXRD of CTZ samples. Abbreviations as per table 1. 
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Fig. A3. DSC of CTZ samples. Abbreviations as per table 1. 
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Fig. A4. FTIR of: CTZRaw, CTZ5, CTZ0.5, CTZ2.  
	
